GlassScriptPhysician profile
Dalton Reimus
NPI 1700594843
$4,177.30
in general payments reported to CMS, 2019-2025
38 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,460 · 2024: $1,233 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,177.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.77 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $484.29 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $438.65 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $399.25 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.83 | 2023-2025 | Caplyta |
| Pfizer INC. | $165.62 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $157.69 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $148.77 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $144.67 | 2023-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $136.19 | 2023-2025 | |
| Mylan Specialty L.P. | $117.75 | 2023-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.25 | 2023-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $92.01 | 2023-2024 | Quviviq |
| Corcept Therapeutics | $89.66 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $83.85 | 2023-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $75.92 | 2023 | Seglentis |
| Novartis Pharmaceuticals Corporation | $70.49 | 2024-2025 | |
| Astellas Pharma US INC | $70.25 | 2024-2025 | Veozah |
| Vanda Pharmaceuticals INC. | $68.02 | 2025 | Fanapt, Hetlioz |
| Amgen INC. | $64.80 | 2024-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.21 | 2023-2025 | Jardiance |
| Lundbeck LLC | $51.19 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $44.08 | 2023-2025 | Trelegy Ellipta |
| Indivior INC. | $43.03 | 2024-2025 | Sublocade |
| Medtronic, INC. | $41.82 | 2023-2024 | Activos 10 Bone Cement |
| Exact Sciences Corporation | $37.53 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $27.55 | 2023-2024 | Gvoke Hypopen |
| Springworks Therapeutics, INC. | $27.44 | 2025 | Gomekli |
| Edwards Lifesciences Corporation | $26.37 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $21.68 | 2024 | Eliquis |
| Radius Health, INC. | $20.34 | 2023 | Tymlos |
| Phathom Pharmaceuticals, INC. | $19.33 | 2024 | Voquezna |
| Neurelis, INC. | $19.27 | 2023 | Valtoco |
| Ucb, INC. | $17.40 | 2024 | Nayzilam |
| Takeda Pharmaceuticals U.S.A., INC. | $16.27 | 2025 | Trintellix |
| Alvogen INC | $15.78 | 2023 | Teriparatide |
| Viatris Specialty LLC | $15.36 | 2025 | Yupelri |
| Tonix Medicines, INC. | $13.92 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalton Reimus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.